Breaking News, Collaborations & Alliances

MEDI&GENE Enters Catalyze Agreement with Lilly to Advance Obesity Therapeutic

Brings Lilly’s expertise in molecule engineering and development to MEDI&GENE’s asset.

MEDI&GENE, a biopharmaceutical company developing therapeutics for metabolic diseases, has entered into a Catalyze agreement with Eli Lilly and Company (Lilly) to advance a next-generation therapeutic for obesity.

Under the agreement, Lilly ExploR&D will bring Lilly’s expertise in molecule engineering and development to a MEDI&GENE asset, with the goal to advance the program to clinical trial readiness. Lilly ExploR&D is part of the Lilly Catalyze360 suite of offerings designed to empower biotech innovation by providing access to strategic capital, lab space and technology, and research and development capabilities.

“We are excited to work with Lilly to advance a next-generation obesity drug candidate. We believe this collaboration will accelerate clinical development and help bring differentiated solutions to patients with obesity,” said Min-Jeong Shin, CEO of MEDI&GENE.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters